Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie

Reuters

Feb 09

Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie

Edding Genor Group Holdings Ltd. hat bekanntgegeben, dass im Rahmen der Phase-II-Studie des innovativen kleinen Nukleinsäure-Arzneimittels EDP167 die erste Probandenbehandlung erfolgreich abgeschlossen wurde. Die multizentrische, offene Studie untersucht die Wirksamkeit und Sicherheit von EDP167 bei erwachsenen Patienten mit homozygoter familiärer Hypercholesterinämie (HoFH), wobei der primäre Endpunkt die Veränderung des LDL-Cholesterinspiegels nach 24 Wochen ist. Ergebnisse aus einer vorangegangenen Phase-I-Studie zeigten ein günstiges Sicherheits- und Verträglichkeitsprofil. Die detaillierten Daten sollen auf einer medizinischen Konferenz im Jahr 2026 präsentiert werden.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018764), on February 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610506655"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610506655\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610506655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610506655","market":"nz","top_or_hot":-1,"title":"Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edding Genor Group Holdings Ltd. hat bekanntgegeben, dass im Rahmen der Phase-II-Studie des innovativen kleinen Nukleinsäure-Arzneimittels EDP167 die erste Probandenbehandlung erfolgreich abgeschlossen wurde. Die multizentrische, offene Studie untersucht die Wirksamkeit und Sicherheit von EDP167 bei erwachsenen Patienten mit homozygoter familiärer Hypercholesterinämie (HoFH), wobei der primäre Endpunkt die Veränderung des LDL-Cholesterinspiegels nach 24 Wochen ist. Ergebnisse aus einer vorangegangenen Phase-I-Studie zeigten ein günstiges Sicherheits- und Verträglichkeitsprofil. Die detaillierten Daten sollen auf einer medizinischen Konferenz im Jahr 2026 präsentiert werden.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018764), on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-09 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edding Genor Group Holdings Ltd. hat bekanntgegeben, dass im Rahmen der Phase-II-Studie des innovativen kleinen Nukleinsäure-Arzneimittels EDP167 die erste Probandenbehandlung erfolgreich abgeschlossen wurde. Die multizentrische, offene Studie untersucht die Wirksamkeit und Sicherheit von EDP167 bei erwachsenen Patienten mit homozygoter familiärer Hypercholesterinämie (HoFH), wobei der primäre Endpunkt die Veränderung des LDL-Cholesterinspiegels nach 24 Wochen ist. Ergebnisse aus einer vorangegangenen Phase-I-Studie zeigten ein günstiges Sicherheits- und Verträglichkeitsprofil. Die detaillierten Daten sollen auf einer medizinischen Konferenz im Jahr 2026 präsentiert werden.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018764), on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL1zJ3S7:1","article_id":"2610506655","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610506655","pubTimestamp":1770596748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 09, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","06998":"亿腾嘉和","BK1574":"生物医药B类股"},"translate_title":"Edding Genor启动EDP167治疗纯合子家族性高胆固醇血症的II期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":0.9},"content_text":"Edding Genor startet Phase-II-Studie mit EDP167 bei Homozygoter Familiärer Hypercholesterinämie\n    \n\n        Edding Genor Group Holdings Ltd. hat bekanntgegeben, dass im Rahmen der Phase-II-Studie des innovativen kleinen Nukleinsäure-Arzneimittels EDP167 die erste Probandenbehandlung erfolgreich abgeschlossen wurde. Die multizentrische, offene Studie untersucht die Wirksamkeit und Sicherheit von EDP167 bei erwachsenen Patienten mit homozygoter familiärer Hypercholesterinämie (HoFH), wobei der primäre Endpunkt die Veränderung des LDL-Cholesterinspiegels nach 24 Wochen ist. Ergebnisse aus einer vorangegangenen Phase-I-Studie zeigten ein günstiges Sicherheits- und Verträglichkeitsprofil. Die detaillierten Daten sollen auf einer medizinischen Konferenz im Jahr 2026 präsentiert werden.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018764), on February 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}